Advertisement
Advertisement
VIR
Vir Biotechnology, Inc. Common Stock
8.55
USDSponsored
-0.11
-1.27%
Aug 03, 09:35 UTC -4
Open
VIR Earnings Reports
Positive Surprise Ratio
VIR beat 10 of 27 last estimates.
37%
Next Report
In 2 Days
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$218.62M
/$0.33
Implied change from Q1 26 (Revenue/ EPS)
+753764.00%
/-138.82%
Implied change from Q2 25 (Revenue/ EPS)
+17908.28%
/-141.25%
Vir Biotechnology, Inc. Common Stock earnings per share and revenue
On May 06, 2026, VIR reported earnings of -0.85 USD per share (EPS) for Q1 26, missing the estimate of -0.09 USD, resulting in a -781.74% surprise. Revenue reached 29.00 thousand, compared to an expected 110.38 million, with a -99.97% difference. The market reacted with a +2.80% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.33 USD, with revenue projected to reach 218.62 million USD, implying an decrease of -138.82% EPS, and increase of 753764.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Vericel Corporation
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.02
Actual
$0.04
Surprise
+239.37%
Anavex Life Sciences
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.06
Surprise
+15.97%
Compugen Ltd
Report Date
Aug 03, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+14.22%
Alnylam Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.58
Actual
$1.21
Surprise
-23.70%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q1 26
Estimate
$1.25
Actual
$1.31
Surprise
+4.74%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
Krystal Biotech, Inc. Common Stock
Report Date
Aug 03, 2026 For Q2 26
Estimate
$1.68
Actual
$1.79
Surprise
+6.00%
TG Therapeutics, Inc.
Report Date
Aug 03, 2026 For Q2 26
Estimate
$0.33
Actual
$0.05
Surprise
-84.97%
Twist Bioscience Corporation Common Stock
Report Date
Aug 03, 2026 For Q3 26
Estimate
-$0.50
Actual
-$0.56
Surprise
-11.20%
FAQ
What were Vir Biotechnology, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Vir Biotechnology, Inc. Common Stock reported EPS of -$0.85, missing estimates by -781.74%, and revenue of $29.00K, -99.97% below expectations.
How did the market react to Vir Biotechnology, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 2.8%, changed from $10.01 before the earnings release to $10.29 the day after.
When is Vir Biotechnology, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Vir Biotechnology, Inc. Common Stock's next earnings report?
Based on 6
analysts, Vir Biotechnology, Inc. Common Stock is expected to report EPS of $0.33 and revenue of $218.62M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement